
    
      Primary Objective Estimate event free survival (EFS) (relapse, progression, or death) rate
      one year after transplant.

      Secondary Objectives:

        1. Estimate the cumulative incidences of severe acute grade III or higher GVHD, chronic
           GVHD (overall and by extent)

        2. Estimate the cumulative incidence of systemic steroid initiation,

        3. Summarize the graft failure frequency,

        4. Summarize the kinetics of neutrophil and platelet recovery, and kinetics of donor
           chimerism in unsorted and CD3+ sorted peripheral blood.

        5. Summarize major toxicities and complications associated with the transplantation
           procedure selected toxicities.

      Exploratory Objectives:

      Explore the association between the amount of donor T cell chimerism at ~ Day 28 and
      patient/graft characteristics (e.g., prior therapies, graft cell dose) and transplantation
      outcomes (sustained engraftment, relapse or progression, GVHD).
    
  